



# Graphene Frontiers

**Bruce Willner**  
**Chief Science Officer**

<http://www.graphenefrontiers.com>

## Characterizing Disruptive Innovation: Meet the 'Disruptors'

The Disruption Myth and Gaps in the Innovation Ecosystem  
Government-University-Industry Research Roundtable Meeting

National Academies, Washington, DC


October 20-21, 2015




Government | University | Industry  
RESEARCH ROUNDTABLE



**six sensors**  
elevate your platform



# Today's Process – Clinical Laboratory Tests



Testing

Wait days for Results (or longer).

- Requires sending samples to a laboratory.
- The analysis is time-consuming, requiring several wet laboratory steps conducted by a skilled laboratory technician.
- Higher sensitivity, quantified results may take longer, if possible at all.

# 1st Gen POC Diagnostics: Not Good Enough

Typical samples




Common test formats

Lateral-flow test



Vertical-flow test



Manually read dipsticks

- **Limited sensitivity**
- **Inaccurate**
- **Slow**

# Next Gen POC Diagnostics: Quantum Leap

## Samples

Capillary blood, oral fluid, urine, breath, and other samples



## Multiple test formats

Handheld lab-on-a-chip devices  
Disposable tests (no instruments)  
Doctor's office desk-based devices



Devices will fully automate testing and analysis or display of results




## Transmission of results

Devices are likely to have wireless connectivity to transmit result data




# Graphene Biosensor




**GFET = Graphene Field Effect Transistor**

# Graphene Structure

- Hexagonal structure
- Short, strong bonds 1.42A



# Graphene Properties



**Two Dimensional**

*Highly sensitive*

**Inert with Few Defects**

*Highly specific*

**Conductive**


*Strong signal*


**Strong**

*Robust devices*

**Make it ideal for biosensing applications...**


# GFET Functionalization







# Biosensor Features

- Devices fabricated by IC lithography processes.
- Compact active area.
- High density arrays.
- Highly scalable production
- Device Array Integration for a Lab-on-a-chip



# Example Results: Naltrexone Detection




**Clear signal to picograms per milliliter**

Lerner, M. B., et al. (2014). *Nano Letters*, 14(5), 2709–2714.

# Demonstrated Results: **Multiple Proteins**

- **IL-6**
- **Troponin I**
- **Borrelia burgdorferi**
- **Osteopontin (OPN)**
- **Salmonella**


**Signal @ 1pg/mL (30 fM)**



# Biosensors:

**\$20B**

## Global Multiplexed Diagnostics Market Revenue, By Technology, 2012 (USD Million)





Source: KOL Opinions, Company Annual Reports, Expert Interviews, Investing Publications, Press Releases & TMR Analysis

**Low/Medium Density Multiplexed Assays: >\$2B**

*The Disruption Myth and Gaps in the Innovation Ecosystem  
National Academies, Washington, DC October 20-21, 2015*



# Comparison with ELISA



	ELISA	GFET
Limit of Detection (LOD)	<b>1-20pg/ml</b>	<b>100x-1000x better than ELISA</b>
Ability to Multiplex	<b>No</b> (1 antibody per run)	<b>Yes</b>
Speed	<b>Hours</b> for incubation and processing	Sample to results in <b>minutes</b>
Cost	Expensive Optical Readers	All electronic, lower cost
Ease of Use	Trained <b>Lab Tech Needed</b>	After sample obtained, the rest is <b>automated</b>
Specificity of detection	Relies on secondary detection antibody <b>Higher false positives</b>	<b>Specific</b> and direct detection – all electronic

# Go To Market: Path to Revenue

## 1. Research Use Only

- Currently available through Sigma-Aldrich

## 2. Real-time Biomonitor

## 3. Point of Care Diagnostics

- Developed and distributed via partners\*

# Commercialization Challenges

Point of Care Diagnostics is the large application.


Challenges:

- A large, established industry.
- Healthcare industry does not like change.
- Many different tests for many different conditions.
- Approval path is slow and expensive and needs to be repeated for each test.
- Revenue Path is critical (i.e. HCPCS Codes)

Our Solution:

- Begin targeting diagnostic tests with impact.
- Partner with existing diagnostic companies.
- Focus our work on our expertise and team with others for our shortcomings.

# Proof of Concept Program: **Troponin I**



# POC Diagnostics: Potential Partners



GE Healthcare



Siemens Healthcare  
Diagnostics



*The Disruption Myth and Gaps in the Innovation Ecosystem*  
National Academies, Washington, DC October 20-21, 2015



# Company Origin

- Spin-out from the University of Pennsylvania.
  - Formed in 2011
- Formed around IP for low-cost, production of graphene films (developed in the Physics Department lab of A.T. Charlie Johnson).
- Additional graphene production technology developed at Graphene Frontiers.




# Problem: Commercial Production



- 1) Low Volume
- 2) Expensive
- 3) Not Uniform
- 4) Harsh Chemicals



# Breakthrough: Problem Solved!




- Developed Processes For:
- Scalable single atomic layer graphene deposition
- Graphene handling
  - Transfer of the graphene to different substrates.




National Science Foundation  
WHERE DISCOVERIES BEGIN


# Graphene Chemical Vapor Deposition





## Atmospheric Pressure Chemical Vapor Deposition



# Continuous Graphene Transfer




- Hydrolysis-Assisted Mechanical Separation



# Scaled Graphene Production

2010



**1 cm<sup>2</sup> > \$10,000**

2012




**1 cm<sup>2</sup> < \$10**


2016



**1 cm<sup>2</sup> < \$0.01**



# Markets: Size and Timing



Market  
Ready:



*The Disruption Myth and Gaps in the Innovation Ecosystem*  
National Academies, Washington, DC October 20-21, 2015


# Thank You



**Graphene**  
Frontiers




**Bruce Willner - Chief Science Officer**  
<http://www.graphenefrontiers.com>




# Rigid Substrate Transfer


- Transfer to rigid surfaces using an intermediate transfer substrate.
- Patterned Transfer
  - Pattern the graphene through selective adhesion of the graphene.



# Vapor Phase Detection



# Vapor Phase Detection



Kybert, N., et al (2014). *Nano Research*, 7(1), 95–103.